Located in Portland, Oregon, Calypte Biomedical gained recognition by developing in vitro testing products to improve the diagnosis of Human Immunodeficiency Virus (HIV) infection and other sexually transmitted chronic diseases. Today, Calypte Biomedic took a major step towards prominence with the announcement they have successfully completed internal studies of its new Aware HIV-1/2 oral fluid rapid test for the US and international markets.
The trials were conducted in South Africa and in the US and generated data from 577 subjects at various levels of risk for the HIV infection. In the combined results, the Aware HIV-1/2 oral fluid rapid test displayed an accuracy level of 100%.
Leading the team at Calypte Biomedical is Adel Karas who serves as the Chairman and CEO of the young company. Commenting on the effects of this testing, Karas was quoted as saying, “I am pleased that Calypte’s new Aware HIV-1/2 rapid test has been successful in these studies. We strongly believe that our product has the potential to significantly improve HIV testing and early diagnosis.”
Based on these results, Calypte has contacted the FDA and started the process to conduct clinical trials in the second half of 2011. With the potential for clinical trials coming, Calypte Biomedical may be a rising star in the healthcare sector.
To learn more about this breaking news or the company as a whole, visit their website at: www.calypte.com